Nephro Care India Ltd (NEPHROCARE) — shareholding pattern, promoter holding, financials and share price
About Nephro Care India Ltd (NEPHROCARE)
Nephro Care India Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as NEPHROCARE and on the BSE under scrip code 92991. Its ISIN is INE0SUN01013.
Incorporated in 2014, Nephro Care India Ltd is a healthcare provider that specializes in the treatment of kidney- related diseases [1]
Nephro Care India Limited is a healthcare service provider specializing in comprehensive renal care solutions based in Kolkata. They offer a one-stop treatment center catering to lifestyle, physiological, and spiritual wellness for renal patients.
Founded by Dr. Pratim Sengupta in 2014, the company transitioned from a private to a public limited company in March 2024. Utilizing a skilled team and sufficient infrastructure, Nephro Care provides non-invasive renal services.
Listed peers in Healthcare Service Provider: Star Imaging and Path Lab Ltd, Vijaypd Ceutical Ltd, Aspira Pathlab & Diagnostics Ltd, Invicta Diagnostic Ltd, Choksi Laboratories Ltd, Modern Diagnostic & Research Centre Ltd.
Valuation & Returns
10 Jul 2026At ₹71.45 a share on 10 Jul 2026, Nephro Care India Ltd (NEPHROCARE) was valued at a price-to-earnings ratio of 35.02x against an industry P/E of 61.73x and a price-to-book of 2.07x on a book value of ₹34.49 per share. Solomo computes return on equity of 5.93% and return on capital employed of 8.44% from filed results.
- P/E
- 35.02x
- Industry P/E
- 61.73x
- P/B
- 2.07x
- EPS (TTM)
- ₹2.38
- Book value / share
- ₹34.49
- ROE
- 5.93%
- ROCE
- 8.44%
- Debt / equity
- 0x
- Dividend yield
- 0%
- 52-week range
- ₹50.05 – ₹183
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Nephro Care India Ltd (NEPHROCARE) reported revenue of ₹88.71 crore, net profit of ₹3.37 crore and earnings per share of ₹2.04. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹26.97 crore and net profit ₹1 crore (consolidated).
| Metric | Mar 2026 |
|---|---|
| Revenue (₹ cr) | 88.71 |
| Net profit (₹ cr) | 3.37 |
| EPS (₹) | 2.04 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 143.45% | 137.77% | 67.20% |
| Profit growth | - | - | -17.46% |
| Stock price CAGR | - | - | -52% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 61.71% of Nephro Care India Ltd (NEPHROCARE) (unchanged from the previous quarter). Market capitalisation was ₹118 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 61.71% | - | - | - | - |
| Mar 2026 | 61.71% | - | - | - | - |
| Sep 2025 | 61.47% | - | - | - | - |
| Mar 2025 | 61.44% | - | - | - | - |
| Dec 2024 | 61.38% | - | - | - | - |
| Sep 2024 | 61.38% | - | - | - | - |